Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward T Richardson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Breast Cancer|March 2, 2020
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast CancerRomualdo Barroso-Sousa, Ian E Krop, Lorenzo Trippa, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancerAdrienne G Waks, Tanya E Keenan, Tianyu Li, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
Annals of the Rheumatic Diseases|November 11, 2019
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritisPui Y Lee, Grant S Schulert, Scott W Canna, et al.
Cell|April 21, 2022
Quiescent cancer cells resist T cell attack by forming an immunosuppressive nichePilar Baldominos, Alex Barbera-Mourelle, Olga Barreiro, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Cancer Research|July 14, 2023
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast CancerFrancisco Hermida-Prado, Yingtian Xie, Shira Sherman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 5, 2026
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide ImagesBrittany McKelvey, Pedro A Torres-Saavedra, Jessica Li, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Breast Cancer|March 2, 2020
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast CancerRomualdo Barroso-Sousa, Ian E Krop, Lorenzo Trippa, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancerAdrienne G Waks, Tanya E Keenan, Tianyu Li, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
Annals of the Rheumatic Diseases|November 11, 2019
Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritisPui Y Lee, Grant S Schulert, Scott W Canna, et al.
Cell|April 21, 2022
Quiescent cancer cells resist T cell attack by forming an immunosuppressive nichePilar Baldominos, Alex Barbera-Mourelle, Olga Barreiro, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Cancer Research|July 14, 2023
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast CancerFrancisco Hermida-Prado, Yingtian Xie, Shira Sherman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 5, 2026
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide ImagesBrittany McKelvey, Pedro A Torres-Saavedra, Jessica Li, et al.
Pageof 2